130 related articles for article (PubMed ID: 20334788)
1. [Maintenance treatment of non-small cell lung cancer].
Hansen O; Schytte T
Ugeskr Laeger; 2010 Mar; 172(12):954. PubMed ID: 20334788
[No Abstract] [Full Text] [Related]
2. Second-line therapeutic options in non-small-cell lung cancer.
Vansteenkiste J
Lung Cancer; 2006 Dec; 54 Suppl 2():S15-8. PubMed ID: 17064813
[TBL] [Abstract][Full Text] [Related]
3. The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.
Comis RL
Oncologist; 2005 Aug; 10(7):467-70. PubMed ID: 16079313
[No Abstract] [Full Text] [Related]
4. Second-line treatment for advanced non-small cell lung cancer: how to design a clinical trial for a new agent?
Paesmans M; Berghmans T; Sculier JP
Lung Cancer; 2007 Feb; 55(2):135-6. PubMed ID: 17118490
[No Abstract] [Full Text] [Related]
5. A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer.
Nuijten MJ; de Castro Carpeño J; Chouaid C; Vergnenègre A; Grossi F; Bischoff H; Heigener D; Walzer S
Lung Cancer; 2012 Jun; 76(3):465-71. PubMed ID: 22153602
[TBL] [Abstract][Full Text] [Related]
6. [The TULUNG clinical registry].
Spelda S; Skřičková J; Bortlíček Z; Hejduk K; Pešek M; Zatloukal P; Kolek V; Salajka F; Koubková L; Tomíšková M; Grygárková Y; Havel L; Hrnčiarik M; Zemanová M; Sixtová D; Roubec J; Coupková H; Košatová K
Klin Onkol; 2012; 25(5):383-4. PubMed ID: 23102201
[No Abstract] [Full Text] [Related]
7. Maintenance therapy in non-small-cell lung cancer.
Stinchcombe TE; West HL
Lancet; 2009 Oct; 374(9699):1398-400. PubMed ID: 19767096
[No Abstract] [Full Text] [Related]
8. Response to pemetrexed chemotherapy in lung adenocarcinoma-bronchioloalveolar carcinoma insensitive to erlotinib.
Manson GV; Ma PC
Clin Lung Cancer; 2010 Jan; 11(1):57-60. PubMed ID: 20085869
[TBL] [Abstract][Full Text] [Related]
9. Continuous pemetrexed treatment for brain metastasis in non-small cell lung cancer--a report of two cases.
Ochi N; Yamane H; Yamagishi T; Takigawa N
Lung Cancer; 2013 Apr; 80(1):111-3. PubMed ID: 23279874
[No Abstract] [Full Text] [Related]
10. The need for third-line treatment in non-small cell lung cancer: an overview of new options.
Syrigos KN; Saif MW; Karapanagiotou EM; Oikonomopoulos G; De Marinis F
Anticancer Res; 2011 Feb; 31(2):649-59. PubMed ID: 21378351
[TBL] [Abstract][Full Text] [Related]
11. [Multi-target tumor therapy].
Krankenpfl J; 2005; 43(1-3):38-9. PubMed ID: 15912831
[No Abstract] [Full Text] [Related]
12. Second-line treatment for non-small-cell lung cancer: one size does not fit all.
Caponi S; Vasile E; Ginocchi L; Tibaldi C; Borghi F; D'Incecco A; Lucchesi M; Caparello C; Andreuccetti M; Falcone A
Clin Lung Cancer; 2010 Sep; 11(5):320-7. PubMed ID: 20837457
[TBL] [Abstract][Full Text] [Related]
13. [New era in cancer therapy. Gefitinib: small molecule--strong action].
Arnheim K
MMW Fortschr Med; 2004 Nov; 146(47):70-1. PubMed ID: 15624666
[No Abstract] [Full Text] [Related]
14. Editorial: Comparative efficacy and cost associated with new agents in the treatment of non-small cell lung cancer (NSCLC).
Mueller E
Lung Cancer; 2010 Aug; 69 Suppl 1():S1-3. PubMed ID: 20727456
[No Abstract] [Full Text] [Related]
15. Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial.
Sun JM; Lee KH; Kim SW; Lee DH; Min YJ; Yun HJ; Kim HK; Song HS; Kim YH; Kim BS; Hwang IG; Lee K; Jo SJ; Lee JW; Ahn JS; Park K; Ahn MJ;
Cancer; 2012 Dec; 118(24):6234-42. PubMed ID: 22674612
[TBL] [Abstract][Full Text] [Related]
16. Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer.
Reddy GK
Clin Lung Cancer; 2005 Nov; 7(3):163-5. PubMed ID: 16354309
[No Abstract] [Full Text] [Related]
17. Adjuvant chemotherapy for non-small cell lung cancer.
D'Amico TA
Semin Thorac Cardiovasc Surg; 2005; 17(3):195-8. PubMed ID: 16253822
[TBL] [Abstract][Full Text] [Related]
18. Pemetrexed and maintenance therapy for non-small cell lung cancer.
Prescrire Int; 2011 Feb; 20(113):39. PubMed ID: 21488588
[No Abstract] [Full Text] [Related]
19. Erlotinib and maintenance therapy of non-small cell lung cancer. Inadequate assessment; authorisation unjustified.
Prescrire Int; 2011 Oct; 20(120):234. PubMed ID: 21970082
[No Abstract] [Full Text] [Related]
20. Pemetrexed for the treatment of non-small-cell lung cancer.
Manegold C; Schmid-Bindert G; Pilz LR
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1195-209. PubMed ID: 19761423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
